Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 16.625 GBX 3.1% Market Closed
Market Cap: 68.5m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Creo Medical Group PLC
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Creo Medical Group PLC
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Creo Medical Group PLC
LSE:CREO
Cash from Financing Activities
ÂŁ4.7m
CAGR 3-Years
720%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Cash from Financing Activities
$258m
CAGR 3-Years
-22%
CAGR 5-Years
21%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cash from Financing Activities
$17m
CAGR 3-Years
N/A
CAGR 5-Years
-32%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Cash from Financing Activities
-ÂŁ7.1m
CAGR 3-Years
-10%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Angle PLC
LSE:AGL
Cash from Financing Activities
ÂŁ7.8m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Cash from Financing Activities
$12.5m
CAGR 3-Years
80%
CAGR 5-Years
29%
CAGR 10-Years
N/A
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
68.5m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.93 GBX
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Creo Medical Group PLC's Cash from Financing Activities?
Cash from Financing Activities
4.7m GBP

Based on the financial report for Jun 30, 2024, Creo Medical Group PLC's Cash from Financing Activities amounts to 4.7m GBP.

What is Creo Medical Group PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-37%

Over the last year, the Cash from Financing Activities growth was -85%. The average annual Cash from Financing Activities growth rates for Creo Medical Group PLC have been 720% over the past three years , -37% over the past five years .

Back to Top